BG
DRNA

Bellevue Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Bellevue Group’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-61,000
Closed -$2.28M – 226
2021
Q2 		$2.28M Sell
61,000
-7,000
-10% -$215K 0.02% 140
2021
Q1 		$1.74M Hold
68,000
– – 0.02% 144
2020
Q4 		$1.5M Buy
+68,000
New +$1.5M 0.02% 149

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Bellevue Group's DRNA Position: Q3 2021 in Review

Bellevue Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 61,000 shares — an estimated $2.28M sold.

Bellevue Group first reported a position in DRNA in Q4 2020 and held it in 3 quarters. The position peaked at $2.28M in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • Bellevue Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Bellevue Group sold 61,000 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $2.28M.
  • Bellevue Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2020 and held it in 3 quarters.
  • Bellevue Group's Dicerna Pharmaceuticals, Inc. position peaked at $2.28M in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.